“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b 4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study (PSORIATYK SCALP)”. 2025. SKIN The Journal of Cutaneous Medicine 9 (2): s528. https://doi.org/10.25251/skin.10.supp.528.